Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results

Table 1 Clinical and demographical data of PE-IVIG-RTX and control group n (%)

	PE-IVIG-RTX group (n = 9)	Control group (n = 12)	P-value
Recipient age at diagnosis, yr	47 (24-65)	52 (26-67)	0.234
Gender (M/F ratio)	5/4	8/4	0.604
Donor age, yr	58 (37-80)	49 (18-82)	0.203
Living donor transplantation	2/9 (22.2)	0/12 (0)	0.086
Previous transplants	1/9 (11.1)	3/12 (25)	0.422
Maximum PRA	0% (0-89)	27.5% (0-95)	0.061
Mismatches HLA A-B-DR, n	2 (1-4)	3 (1-4)	0.639
Previous episodes of acute rejection
(acute AMR – ACR)	1/9 (11.1)-1/9 (11.1)	1/12 (8.3)-1/12 (8.3)	0.586
Immunosuppression: Induction1	9/9 (100)	10/12 (83.3)	0.198
Clinical data at diagnosis
Time between transplantation and diagnosis of cAMR, mo	51 (21-108)	79 (20-258)	0.201
Serum creatinine, mg/dL	1.9 (1.2-3)	1.9 (0.9-3.7)	0.477
GFR2, mL/min	55,4 (23.9-65.4)	42.35 (18.9-88.1)	0.887
Proteinuria, g/d	1.6 (1-4)	1.55 (0.3-7.3)	0.886

¹All patients in both groups were treated with basiliximab except the two patients in control group who received only steroid induction.

²GFR estimated by Cockroft-Gault formula. Data are expressed as median (min-max). GFR: Glomerular filtration rate; PRA: Panel reactive lymphocytotoxicity assay; AMR: Antibody-mediated rejection; ACR: Acute cellular rejection.